Eaton to showcase comprehensive commercial vehicle clutch portfolio at Automechanika Frankfurt
5.9.2024 12:30:00 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced it is showcasing an array of aftermarket clutch solutions for the Europe, Middle East and Africa (EMEA) markets at Automechanika Frankfurt in Hall 3, booth D11. Eaton is displaying its complete line of angle spring clutches, diaphragm spring clutches, concentric pneumatic clutch actuators and ServiceRanger diagnostic solutions for commercial vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905507731/en/
Eaton’s Advantage series automated diaphragm spring clutches are designed for all makes and models of automated manual transmissions (AMT) in the EMEA market. (Photo: Business Wire)
“We are dedicated to expanding our product portfolio to meet the changing needs of the global market and increasing customer relationships in all market channels,” said Tim Bauer, vice president, Aftermarket, Eaton’s Mobility Group.
The angle spring clutches are used for manual transmissions and are offered in two series. The Advantage series features strap drive technology that improves intermediate plate connection for more reliable performance while eliminating lug rattle and fatigue. Additionally, they are designed with a dual-seal release bearing, which allows for best-in-class 80,000-km lube intervals, reducing maintenance downtime. Eaton also offers the EverTough® series, which provides a more cost-effective solution for vehicles older than seven years.
Eaton also will be displaying its Advantage series automated diaphragm spring clutches for all makes and models of automated manual transmissions (AMT) in the EMEA market. These clutches are built to strict OEM quality standards and minimize idling noise while reducing severe vibrations and delivering outstanding performance and extended clutch life.
Eaton will also be showing its electronic clutch actuator that is designed for its UltraShift Plus transmission along with its concentric pneumatic clutch actuators (CPCAs) for DT12®, the Volvo I-Shift and Mack mDRIVE™ AMTs. The CPCAs help optimize vehicle performance by working with a vehicle’s AMT to continuously determine the ideal release position and clutch actuation when the transmission shifts. Many current AMT-equipped trucks are no longer under factory warranty, so fleet customers need reliable parts to complete repairs and maintenance. Replacing the CPCA during clutch service can help save repair time and cost while reducing downtime for unscheduled maintenance.
To support AMTs operating in the market Eaton offers its ServiceRanger™ 4 Pro Plus (SR4 Pro Plus) software. This diagnostic software and service tool is designed to support all Eaton AMTs, hybrid powertrain systems, Advantage Automated Series clutches and Eaton Cummins Automated Transmission Technologies. In addition, there is an “App Center” that allows users to calibrate all makes and models of diaphragm spring clutches and CPCAs that fit DT12®, Volvo® I-Shift and Mack mDRIVE™ AMTs.
“Eaton now offers a complete line of aftermarket clutch products in EMEA for all makes and models of trucks. Whether the truck is one year old or over fifteen years old, we have the clutch portfolio to provide our customers with cost effective solutions to keep their vehicle operating,” said Pawel Kepka, director, Aftermarket EMEA, Eaton’s Mobility Group.
Learn more about Eaton’s aftermarket solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905507731/en/
Contacts
Thomas Nellenbach
Thomas Nellenbach
(216) 333-2876 (cell)
thomasjnellenbach@eaton.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom